Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
hepatocelluar carcinoma |
immunohistochemistry quantitative RT-PCR analysis |
keloid tissue and keloid fibroblasts |
N/A |
N/A |
lncRNA-ATB governs the autocrine secretion of TGF-β2 in KFs |
27090737 |
|
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue, cell lines (SMMC-7721) |
up-regulated |
regulation |
Thus, these findings suggest that?lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. |
24768205 |
LncRNADisease Lnc2Cancer
|
colorectal cancer |
qPCR etc. |
CRC tissue |
up-regulated |
N/A |
High lncRNA-ATB expression was significantly associated with greater tumor size, depth of tumor invasion, lymphatic invasion, vascular invasion, and lymph node metastasis. Additionally, levels of lncRNA-ATB expression were significantly higher in patients with hematogenous metastases. |
25750289 |
LncRNADisease Lnc2Cancer
|
gastric cancer |
qPCR etc. |
gastric cancer tissue, cell lines (MKN1, MKN7, MKN28, MKN45, MKN74 etc.) |
differential expression |
interaction |
The high lncRNA-ATB group experienced a lower overall survival rate compared with the low lncRNA-ATB group, and multivariate analysis indicated that lncRNA-ATB was an independent prognostic factor (hazard ratio 3.50; 95 % CI 1.73-7.44; p = 0.0004).LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGFb/miR-200s/ZEB axis, resulting in a poor prognosis in GC.LncRNA-ATB is a novel biomarker of lncRNA, indicative of a poor prognosis in GC patients. |
25986864 |
Lnc2Cancer
|
pancreatic cancer |
qPCR etc. |
pancreatic cancer and paired adjacent normal pancreatic tissues, cell lines (HPDE6c-7) |
down-regulated |
expression |
We found that lncRNA-ATB expression was decreased in pancreatic cancer tissues and pancreatic cancer cell lines. Low lncRNA-ATB expression levels were significantly correlated with lymph node metastases (yes vs. no, P = 0.009), neural invasion (positive vs. negative, P = 0.049), and clinical stage (early stage vs. advanced stage, P = 0.014). Moreover, patients with low lncRNA-ATB expression levels exhibited markedly worse overall survival prognoses (P < 0.001). Multivariate analysis indicated that decreased lncRNA-ATB expression was an independent predictor of poor prognosis in pancreatic cancer patients (P = 0.005). |
26482611 |
Lnc2Cancer
|
colon cancer |
qPCR etc. |
colon cancer tissues |
up-regulated |
interaction |
LncRNA-ATB was upregulated in colon cancer tissues compared with adjacent mucosa. LncRNA-ATB levels were also higher in metastatic cancer tissues. Among the three highly invasive colon cancer cell lines, lncRNA-ATB levels were relatively higher with concurrent low levels of E-cad compared with levels in the three low-invasive cell lines. LncRNA-ATB expression correlated with pN stage and AJCC stage. Striking differences were observed in overall survival and disease-free survival in cases with both high lncRNA-ATB expression and low E-cad expression. Reduction of lncRNA-ATB increased expression of epithelial markers E-cad, ZO-1, and decreased expression of mesenchymal markers ZEB1 and N-cadherin (N-cad), and significantly influenced colon cancer cell progression. Plasma lncRNA-ATB was upregulated in colon cancer patients one month after surgery. |
26487301 |
Lnc2Cancer
|
|